

Alicante, 22nd May 2024

COMMUNICATION – MARKET NOTICE - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter “FacePhi” or “the Company”) hereby notifies the following:

Last 13th of May, the Company delivered a Privileged Information informing about the addendum granted with Nice & Green agreeing to cancel new convertible bonds issuance. It was also confirmed that conversion conditions for the tranches already issued, remained.

In light of the above, Nice & Green notified to the Company and exercised its right to convert 120 Notes (2nd and 3rd Tranche 2024) for a conversion amount of 1,200,000 euros.

As a result of the foregoing, the Company will grant a capital increase title deed to cover the conversion of that said Notes. The 701,303 new shares of the Company are issued with an issuing price of 1,7111 euros (issue premium 1,6711 euros plus 0.04 euros of nominal value).

After this capital increase has been granted, the share capital will set at the sum of € 903.574,04 represented by 22.589.351 shares of € 0.04 nominal value each, of the same class, equal, cumulative and indivisible.

Following the exercise of these 120 convertible bonds, series "2nd & 3rd Tranche 2024" have been redeemed, remaining 60 bonds to be converted corresponding to the 4th tranche of 2024. We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró
Chairman of the Board of Directors